SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Sjöwall Christopher) "

Sökning: WFRF:(Sjöwall Christopher)

  • Resultat 121-130 av 167
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
121.
  • Sjöwall, Christopher, et al. (författare)
  • Clinical Heterogeneity, Unmet Needs and Long-Term Outcomes in Patients with Systemic Lupus Erythematosus
  • 2022
  • Ingår i: Journal of Clinical Medicine. - : MDPI. - 2077-0383. ; 11:22
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
    • The clinical presentation of systemic lupus erythematosus (SLE) is highly heterogeneous, ranging from mild disease limited to skin and joint involvement to life-threatening conditions with renal impairment, severe cytopenias, central nervous system disease, and thromboembolic events [...]
  •  
122.
  • Sjöwall, Christopher, et al. (författare)
  • Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis).
  • 2018
  • Ingår i: Rheumatology. - : oxford academic. - 1462-0324 .- 1462-0332. ; 57:8, s. 1400-1407
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives: The aim was to describe the clinical characteristics and epidemiology of hypocomplementaemic urticarial vasculitis (HUV; anti-C1q vasculitis) in two geographically defined areas of Sweden.Methods: In the health-care districts surrounding Skåne University Hospital (mean population 950 560) and Linköping University Hospital (mean population 428 503), all incident cases of HUV residing within the study areas at the onset of disease were identified during the years 2000-15. The diagnosis of HUV was confirmed by review of medical records. Only patients meeting the proposed diagnostic HUV criteria and/or the 2012 Chapel Hill consensus definitions in combination with an ever-positive anti-C1q antibody test were included.Results: Sixteen patients (14 females) were identified during the study period. The median (interquartile range) age at diagnosis was 51 (40.7-56.7) years. Median (interquartile range) time of follow-up from diagnosis to 31 December 2015, or death, was 94 (46.5-136.2) months. The most frequent manifestations at diagnosis were urticaria (100%), arthritis (88%), followed by biopsy-proven glomerulonephritis (19%), episcleritis/scleritis (19%) and recurrent abdominal pain (13%). The annual incidence rate per million inhabitants was estimated as 0.7 (95% CI: 0.4, 1.1). Sixty-three per cent suffered from pulmonary disease at the last follow-up. Two patients died during the follow-up period. One patient underwent lung transplantation, and two patients proceeded to end-stage renal disease. The point prevalence on 31 December 2015 was 9.5/million (95% CI: 4.5, 14.5).Conclusion: Hypocomplementaemic urticarial vasculitis constitutes a rare, but not always benign condition. Renal and lung manifestations were severe in some cases, highlighting the need for careful screening and monitoring of this potentially serious condition.
  •  
123.
  • Sjöwall, Christopher, et al. (författare)
  • HUVS [Hypocomplementemic Urticarial Vasculitis Syndrome] : sällsynt men inte ofarlig vaskulit associerad med urtikaria [A Rare but Not Always Benign Condition]]
  • 2019
  • Ingår i: Läkartidningen. - : Läkartidningen Förlag AB. - 0023-7205 .- 1652-7518. ; 116
  • Tidskriftsartikel (refereegranskat)abstract
    • Although more than 45 years have passed since hypocomplementemic urticarial vasculitis (HUVS) was first described by McDuffie and colleagues at the Mayo clinic, data on epidemiology, disease outcomes, prognosis and clinical features are scarce. Recently, we published the first epidemiological study of HUVS including data on incidence, prevalence, disease outcomes, prognosis and clinical features using data from two separate Swedish regions during a period of 16 years. The estimation of incidence and prevalence rates indicates that HUVS is rare but not always benign. Renal and lung manifestations were severe in some cases, highlighting the need for careful screening and monitoring of this potentially serious condition. It is reasonable to suspect HUVS in patients with unexplained systemic inflammation combined with >6 months of urticaria. Special attention should be paid to patients with recent-onset dyspnea and proteinuria.
  •  
124.
  • Sjöwall, Christopher, 1975- (författare)
  • Reumatiska systemsjukdomar
  • 2018. - 6
  • Ingår i: Internmedicin. - Stockholm : Liber. - 9789147113262 ; , s. 920-939
  • Bokkapitel (övrigt vetenskapligt/konstnärligt)
  •  
125.
  • Sjöwall, Christopher, et al. (författare)
  • Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis
  • 2009
  • Ingår i: Arthritis Research & Therapy. - : Springer Science and Business Media LLC. - 1478-6362 .- 1478-6354. ; 11:6, s. R188-
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction Serum levels of C-reactive protein (CRP) seldom reflect disease activity in systemic lupus erythematosus (SLE). We have previously shown that autoantibodies against neo-epitopes of CRP often occur in SLE, but that this does not explain the modest CRP response seen in flares. However, we have repeatedly found that anti-CRP levels parallel lupus disease activity, with highest levels in patients with renal involvement; thus, we aimed to study anti-CRP in a material of well-characterized lupus nephritis patients. Methods Thirty-eight patients with lupus nephritis were included. Treatment with corticosteroids combined with cyclophosphamide, mycophenolate mofetil or rituximab was started after baseline kidney biopsy. A second biopsy was taken after ≥ 6 months. Serum creatinine, cystatin C, complement, anti-dsDNA, anti-CRP and urinalysis were done on both occasions. Biopsies were evaluated regarding World Health Organisation (WHO) class and indices of activity and chronicity. Renal disease activity was estimated using the British Isles Lupus Assessment Group (BILAG) index. Results At baseline, 34/38 patients had renal BILAG-A; 4/38 had BILAG-B. Baseline biopsies showed WHO class III (n = 8), IV (n = 19), III to IV/V (n = 3) or V (n = 8) nephritis. Seventeen out of 38 patients were anti-CRP-positive at baseline, and six at follow-up. Overall, anti-CRP levels had dropped at follow-up (P < 0.0001) and anti-CRP levels correlated with renal BILAG (r = 0.29, P = 0.012). A positive anti-CRP test at baseline was superior to anti-dsDNA and C1q in predicting poor response to therapy as judged by renal BILAG. Baseline anti-CRP levels correlated with renal biopsy activity (r = 0.33, P = 0.045), but not with chronicity index. Anti-CRP levels were positively correlated with anti-dsDNA (fluorescence-enhanced immunoassay: r = 0.63, P = 0.0003; Crithidia luciliae immunofluorescence microscopy test: r = 0.44, P < 0.0001), and inversely with C3 (r = 0.35, P = 0.007) and C4 (r = 0.29, P = 0.02), but not with C1q (r = 0.14, P = 0.24). No associations with urinary components, creatinine, cystatin C or the glomerular filtration rate were found. Conclusions In the present study, we demonstrate a statistically significant correlation between anti-CRP levels and histopathological activity in lupus nephritis, whereas a baseline positive anti-CRP test predicted poor response to therapy. Our data also confirm previous findings of associations between anti-CRP and disease activity. This indicates that anti-CRP could be helpful to assess disease activity and response to therapy in SLE nephritis, and highlights the hypothesis of a pathogenetic role for anti-CRP antibodies in lupus nephritis.
  •  
126.
  • Sjöwall, Christopher, et al. (författare)
  • Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease
  • 2015
  • Ingår i: Translational Research. - : Elsevier. - 1931-5244 .- 1878-1810. ; 165:6, s. 658-666
  • Tidskriftsartikel (refereegranskat)abstract
    • The identification of individuals with severe liver fibrosis among patients with chronic liver disease is of major importance when evaluating prognosis, potential risk for complications, and when deciding treatment strategies. Although percutaneous liver biopsy is still considered a "gold standard" for staging of liver fibrosis, attempts to find reliable noninvasive markers of liver fibrosis are frequent. Inflammation is essential for the progression of fibrosis. The urokinase plasminogen activator and its receptor have been associated with hepatic inflammation and fibrosis in mice. High serum concentrations of soluble urokinase plasminogen activator receptor (suPAR) are suggested to be involved in inflammation, tissue remodeling, and cancer metastasis. Here, we evaluated serum suPAR as a noninvasive test to detect liver fibrosis in 82 well-characterized patients with nonalcoholic fatty liver disease (NAFLD), and in 38 untreated patients with chronic hepatitis C virus (HCV) infection at the time of their first liver biopsy. suPAR levels were increased in chronic liver disease compared with blood donors (P < 0.001). Patients with HCV had higher suPAR concentrations than patients with NAFLD (P < 0.002). suPAR levels were associated with the severity of fibrosis, particularly in NAFLD, but did not correlate with inflammation. Regarding the performance in predicting severity of fibrosis, suPAR was essentially as good as other commonly used noninvasive fibrosis scoring systems. The results in HCV confirm previous observations. However, this is the first study to investigate suPAR as a biomarker in NAFLD, and the results indicate that suPAR may constitute a severity marker related to fibrosis and prognosis rather than reflecting inflammation.
  •  
127.
  • Sjöwall, Christopher, et al. (författare)
  • Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases
  • 2017
  • Ingår i: Lupus. - : SAGE PUBLICATIONS LTD. - 0961-2033 .- 1477-0962. ; 26:12, s. 1333-1338
  • Tidskriftsartikel (refereegranskat)abstract
    • Although the putative therapeutic options for patients with systemic lupus erythematosus (SLE) are steadily increasing, refractory disease is indeed a major challenge to many clinicians and patients. The proteasome inhibitor bortezomib - approved for the treatment of multiple myeloma since the beginning of this century - was recently reported successful in twelve cases of refractory SLE by German colleagues. Herein, we describe two Swedish SLE cases with refractory renal and pulmonary manifestations that were rescued by bortezomib as induction of remission followed by monthly doses of belimumab. The patients were carefully monitored with regard to disease activity and renal function. Anti-dsDNA and anti-C1q antibodies, complement proteins and lymphocyte subsets were analysed in consecutive samples. In December 2016, the patients had been in clinical remission post bortezomib administration for a period of 28 and 22 months, respectively. Potential benefits of using belimumab as maintenance therapy to prevent regeneration of autoreactive B cell clones are discussed.
  •  
128.
  • Sjöwall, Christopher, et al. (författare)
  • Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus
  • 2018
  • Ingår i: Journal of Immunology Research. - : HINDAWI LTD. - 2314-8861 .- 2314-7156.
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective. Anti-double-stranded (ds) DNA and anti-C1q autoantibodies are useful tools in the assessment of disease activity and nephritis in systemic lupus erythematosus (SLE) patients. This study aimed to explore the utility of these antibodies along with anti-Ku antibodies in an oligoparametric model approach for the assessment of disease activity and lupus nephritis. Methods. Samples from 261 well-characterized SLE patients were tested using chemiluminescent immunoassays (CIA) for anti-dsDNA and anti-Ku antibodies as well as by anti-C1q antibody ELISA (Inova Diagnostics, USA). Of these SLE patients, 26.4% had lupus nephritis (LN) at the time of blood draw or had a history of LN, and modified SLE disease activity index-2K (SLEDAI) scores were used to assess disease activity. Results. All three antibodies demonstrated higher prevalence and higher antibody levels in active versus inactive SLE patients and in LN versus non-LN patients. When oligoparametric analysis was performed, the likelihood of LN and patients with active disease increased with dual and triple positivity. Conclusions. Anti-dsDNA and anti-C1q antibodies are useful tools to identify disease activity and/or renal involvement in SLE patients. In addition, the combination of those antibodies in a two-parametric score might improve the clinical utility of those markers.
  •  
129.
  • Skoglund, Caroline, 1981-, et al. (författare)
  • C-reactive protein and C1q regulate platelet adhesion and activation on adsorbed immunoglobulin G and albumin.
  • 2008
  • Ingår i: Immunology and cell biology. - : Wiley. - 0818-9641 .- 1440-1711. ; 86:5, s. 466-74
  • Tidskriftsartikel (refereegranskat)abstract
    • Blood platelets and C-reactive protein (CRP) are both used clinically as markers of ongoing inflammation, and both participate actively in inflammatory responses, although the biological effects are still incompletely understood. Rapidly adhering platelets express receptors for complement factor 1q (C1q) and the Fc part of immunoglobulin G (IgG), and CRP is known to activate/regulate complement via C1q binding, and to ligate FcgammaRs. In the present study, we used normal human IgG pre-adsorbed to a well-characterized methylated surface as a model solid-phase immune complex when investigating the effects of CRP and C1q on platelet adhesion and activation. Protein adsorption was characterized using ellipsometry and polyclonal antibodies, and human serum albumin (HSA) and non-coated surfaces were used as reference surfaces. Platelet adhesion to IgG and HSA was inhibited by both C1q and CRP. Furthermore, CRP (moderately) and C1q (markedly) decreased the spreading of adhering platelets. The combination of C1q and CRP was slightly more potent in reducing cell adhesion to IgG, and also impaired the adhesion to HSA and non-coated surfaces. Platelet production of thromboxane B2 (TXB(2)) was also reduced by C1q both in the presence and absence of CRP, whereas CRP alone had no effect on TXB(2) production. We conclude that CRP and C1q regulate the behaviour of platelets, and that this may be an important immunoregulatory mechanism during inflammatory conditions.
  •  
130.
  • Skoglund, Oliver, et al. (författare)
  • Fighting Fatigue in Systemic Lupus Erythematosus : Experience of Dehydroepiandrosterone on Clinical Parameters and Patient-Reported Outcomes
  • 2022
  • Ingår i: Journal of Clinical Medicine. - : MDPI. - 2077-0383. ; 11:18
  • Tidskriftsartikel (refereegranskat)abstract
    • Manifestations related to ongoing inflammation in systemic lupus erythematosus (SLE) are often adequately managed, but patient-reported outcome measures (PROMs) support that fatigue and low quality of life (QoL) in the absence of raised disease activity remain major burdens. The adrenal hormone dehydroepiandrosterone (DHEA) has shown potential as a pharmacological agent for managing fatigue in mild SLE. We retrospectively evaluated data on dosage, disease activity, corticosteroid doses, concomitant antirheumatic drugs, and PROMs regarding pain intensity, fatigue, and well-being (visual analogue scales), QoL (EQ-5D-3L) and functional disability. A total of 15 patients with SLE were exposed to DHEA and 15 sex- and age-matched non-exposed SLE patients served as comparators. At baseline, 83% of the DHEA-exposed patients had subnormal DHEA concentration. The 15 subjects prescribed DHEA were exposed during a median time of 12 months (IQR 16.5) [range 3-81] and used a median daily dose of 50 mg of DHEA (IQR 25.0) [range 25-200]. Neither disease activity, nor damage accrual, changed significantly over time among patients using DHEA, and no severe adverse events were observed. Numerical improvements of all evaluated PROMs were seen in the DHEA-treated group, but none reached statistical significance. For DHEA-exposed patients, a non-significant trend was found regarding fatigue comparing baseline and 36 months (p = 0.068). In relation to SLE controls, the DHEA-exposed group initially reported significantly worse fatigue, pain, and well-being, but the differences diminished over time. In conclusion, DHEA was safe, but evidence for efficacy of DHEA supplementation in relation to PROMs were not found. Still, certain individuals with mild SLE, plagued by fatigue and absence of increased disease activity, appear to benefit from DHEA in terms of improved fatigue and QoL. Testing of DHEA concentration in blood should be performed before initiation, and investigation of other conditions, or reasons responsible for fatigue, must always be considered first.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 121-130 av 167
Typ av publikation
tidskriftsartikel (148)
doktorsavhandling (6)
forskningsöversikt (6)
annan publikation (3)
konferensbidrag (3)
bokkapitel (1)
visa fler...
visa färre...
Typ av innehåll
refereegranskat (148)
övrigt vetenskapligt/konstnärligt (19)
Författare/redaktör
Sjöwall, Christopher (146)
Jönsen, Andreas (39)
Rönnblom, Lars (38)
Gunnarsson, Iva (33)
Svenungsson, Elisabe ... (33)
Bengtsson, Anders A. (33)
visa fler...
Leonard, Dag, 1975- (30)
Sandling, Johanna K. (23)
Wetterö, Jonas (23)
Eloranta, Maija-Leen ... (21)
Eriksson, Per (21)
Kastbom, Alf (21)
Rantapää-Dahlqvist, ... (20)
Frodlund, Martina (18)
Sjöwall, Christopher ... (17)
Dahle, Charlotte (16)
Syvänen, Ann-Christi ... (16)
Wirestam, Lina (15)
Skogh, Thomas (15)
Bengtsson, Anders (11)
Saleh, Muna Atallah (11)
Nordmark, Gunnel (10)
Enocsson, Helena (10)
Rönnelid, Johan (9)
Dahlström, Örjan (9)
Parodis, Ioannis, 19 ... (9)
Zickert, Agneta (9)
Alexsson, Andrei (8)
Ahmad, Awais (7)
Imgenberg-Kreuz, Jul ... (7)
Pucholt, Pascal, Dr, ... (7)
Molberg, Øyvind (7)
Lindblad-Toh, Kersti ... (6)
Strevens, Helena (6)
Bengtsson, Christine (6)
Kozyrev, Sergey V. (5)
Andersson, Göran (5)
Holmdahl, Rikard (5)
Gjertsson, Inger, 19 ... (5)
Padyukov, Leonid (5)
Forsblad d'Elia, Hel ... (5)
Jacobsen, Søren (5)
Baecklund, Eva, 1956 ... (5)
Askling, J (5)
Simard, Julia F (5)
Compagno, Michele (5)
Sjöwall, Johanna (5)
Bianchi, Matteo (5)
Enocsson, Helena, 19 ... (5)
Bolin, Karin (5)
visa färre...
Lärosäte
Linköpings universitet (155)
Karolinska Institutet (70)
Uppsala universitet (59)
Lunds universitet (51)
Göteborgs universitet (24)
Umeå universitet (22)
visa fler...
Örebro universitet (13)
Sveriges Lantbruksuniversitet (6)
Stockholms universitet (1)
Linnéuniversitetet (1)
visa färre...
Språk
Engelska (165)
Svenska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (158)
Naturvetenskap (10)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy